{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:58:36Z","timestamp":1761843516962},"reference-count":55,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To investigate baseline factors and neurologic function tests (NFTs) that may predict the development of grade 2 or higher peripheral neuropathy (PN) after treatment with ixabepilone, an epothilone microtubule-stabilizing agent with antitumor activity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Advanced breast cancer patients were treated with ixabepilone (6 mg\/m<jats:sup>2<\/jats:sup>) for 5 consecutive days every 3 weeks in a phase II clinical trial. Physical examinations, questionnaires, nerve conduction studies, and NFTs, including the Jebsen Test of Hand Function (JTH) and the Grooved Pegboard Test (GPT), were performed at baseline and during subsequent cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Forty-seven patients assessable for PN received a median of five cycles of therapy (range, one to 22 cycles). Nine of these patients developed grade 2 PN, and two developed grade 3 PN, with a median time to onset of 144 days (range, 6 to 189 days). Among these 11 patients, PN resolved in eight patients, with a median of 15 days (range, 6 to 346 days) after onset, but PN did not resolve in three patients during follow-ups at 76, 361, and 746 days after onset. GPT and changes of JTH scores at onset of PN were significantly different between patients with and without PN at comparable follow-up times (P = .006 and P = .002, respectively). Changes in GPT and JTH scores over the first two cycles were often associated with the development of PN by exploratory actuarial analysis. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Serious ixabepilone-induced neuropathy was relatively rare on the treatment schedule used. NFTs, such as JTH and GPT, may have utility for predicting PN, but further testing is needed. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.2820","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T22:28:22Z","timestamp":1146263302000},"page":"2084-2091","source":"Crossref","is-referenced-by-count":39,"title":["Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone"],"prefix":"10.1200","volume":"24","author":[{"given":"James J.","family":"Lee","sequence":"first","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Low","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earllaine","family":"Croarkin","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Parks","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene W.","family":"Berman","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Mannan","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[{"name":"From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program; Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Von Hoff DD: The taxoids: Same roots, different drugs. Semin Oncol 24:S13,1997-3-S13-10,"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1007\/s004410050019"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(99)00074-7"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01148489"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008345613594"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008344507482"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.14.1138"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005805907311"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2003.12.006"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1159\/000052132"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.2.250"},{"key":"R15","unstructured":"Jebsen RH, Taylor N, Trieschmann RB, et al: An objective and standardized test of hand function. Arch Phys Med Rehabil 50:311,1969-319,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199109000-00013"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1993.76.3c.1219"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Meneilly GS, Cheung E, Tessier D, et al: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117,1993-M121,","DOI":"10.1093\/geronj\/48.4.M117"},{"key":"R19","unstructured":"Trites R: Neuropsychological Test Manual . Ottawa, Ontario, Canada, Royal Ottawa Hospital, 1977"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2001.17830"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.173"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2003.11.007"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2015"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.063"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh236"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S1540-0352(11)70066-X"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0919-03"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.372"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg415"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:394s,2004,  (suppl 14; abstr 4550)","DOI":"10.1200\/jco.2004.22.90140.4550"},{"key":"R31","unstructured":"McDaid HM, Mani S, Shen HJ, et al: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8:2035,2002-2043,"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.042"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.024"},{"key":"R34","unstructured":"Roche HH, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18,2003,  (abstr 69)"},{"key":"R35","unstructured":"Thomas E, Tabernero J, Fornier M, et al: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 22:8,2003,  (abstr 30)"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000003955.73738.9e"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Hussain M, Faulkner J, Vaishampayan U, et al: Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC): A Southwest Oncology Group Study (S0111). J Clin Oncol 22:384s,2004,  (suppl 14; abstr 4510)","DOI":"10.1200\/jco.2004.22.90140.4510"},{"key":"R38","unstructured":"Vansteenkiste J, Breton J, Sandler A: A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung 932 cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22:626,2003,  (abstr 2519)"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Whitehead RP, McCoy SA, Rivkin SE, et al: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. J Clin Oncol 22:316s,2004,  (suppl 14; abstr 4012)","DOI":"10.1200\/jco.2004.22.90140.4012"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Fojo AT, Menefee ME, Poruchynsky M, et al: A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 23:388s,2005,  (suppl 16; abstr 4541)","DOI":"10.1200\/jco.2005.23.16_suppl.4541"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.577"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.181"},{"key":"R43","unstructured":"Singh DA, Kindler HL, Eng C, et al: Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol 22:281,2003,  (abstr 1127)"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Llombart Cussac A, Baselga J, Manikhas G, et al: Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol 23:25s,2005,  (suppl 16; abstr 586)","DOI":"10.1200\/jco.2005.23.16_suppl.586"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Pavlick AC, Millward M, Farrell K, et al: A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol 22:720s,2005,  (suppl 16; abstr 7542)","DOI":"10.1200\/jco.2004.22.90140.7542"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1177\/107110070002100609"},{"key":"R49","unstructured":"Birke JA, Brandsma JW, Schreuders TA, et al: Sensory testing with monofilaments in Hansen's disease and normal control subjects. Int J Lepr Other Mycobact Dis 68:291,2000-298,"},{"key":"R50","unstructured":"Liveson JA, Ma DM: Laboratory Reference for Clinical Neurophysiology . Philadelphia, PA, F.A. Davis Company, 1992"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R52","unstructured":"Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163,1966-170,"},{"key":"R53","unstructured":"Roch\u00e9 H, Delord JP, Bunnell CA, et al: Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-na\u00efve or taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 21:59a,2002,  (abstr 223)"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2061"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.513"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3353"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.2820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:20:35Z","timestamp":1653513635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.2820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["10.1200\/JCO.2005.04.2820"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.2820","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}